An alternative approach to confirm mixed lineage involvement in acute leukemia with KMT2A rearrangement-an illustrative report.

IF 2.3 Q2 HEMATOLOGY

Blood Research Pub Date : 2023-06-30 DOI:10.5045/br.2023.2023084

Debadrita Ray, Sreejesh Sreedharanunni, Anand Balakrishnan, Praveen Sharma, Nabhajit Mallik, Srinivasan Peyam, Man Updesh Singh Sachdeva

{"title":"An alternative approach to confirm mixed lineage involvement in acute leukemia with <i>KMT2A</i> rearrangement-an illustrative report.","authors":"Debadrita Ray, Sreejesh Sreedharanunni, Anand Balakrishnan, Praveen Sharma, Nabhajit Mallik, Srinivasan Peyam, Man Updesh Singh Sachdeva","doi":"10.5045/br.2023.2023084","DOIUrl":null,"url":null,"abstract":"REFERENCES 1. Munker R, Labopin M, Esteve J, Schmid C, Mohty M, Nagler A. Mixed phenotype acute leukemia: outcomes with allogeneic stem cell transplantation. A retrospective study from the Acute Leukemia Working Party of the EBMT. Haematologica 2017; 102:2134-40. 2. Shimoni A. Relapse of acute leukemia after a second allogeneic stemcell transplantation; is there any hope for cure? Bone Marrow Transplant 2022;57:336-7. 3. DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 2020;383:617‐29. 4. Schuler E, Wagner-Drouet EM, Ajib S, et al. Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group. Ann Hematol 2021;100:959‐68. 5. Qasrawi A, Gomes V, Chacko CA, et al. Acute undifferentiated leukemia: data on incidence and outcomes from a large population-based database. Leuk Res 2020;89:106301. 6. Pan R, Hogdal LJ, Benito JM, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov 2014;4:362‐75. 7. Fleischmann M, Scholl S, Frietsch JJ, et al. Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia. J Cancer Res Clin Oncol 2022;148:3191‐202. 8. Pratz KW, Jonas BA, Pullarkat V, et al. Measurable residual disease response and prognosis in treatment-naïve acute myeloid leukemia with venetoclax and azacitidine. J Clin Oncol 2022; 40:855‐65. 9. Wang N, He J, Liu F. Venetoclax in combination with hypomethylating agents for the treatment of treatment-naive B/myeloid mixed-phenotype acute leukemia and relapsed/refractory acute myeloid leukemia: a report of 3 cases. Chemotherapy 2022;67:178-82. 10. Klocke H, Dong ZM, O'Brien C, et al. Venetoclax and decitabine for T/myeloid mixed-phenotype acute leukemia not otherwise specified (MPAL NOS). Case Rep Hematol 2020;2020:8811673. 11. Zhao P, Ni M, Ma D, et al. Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation. Ann Hematol 2022;101:119‐30. 12. Lasica M, Anderson MA. Review of venetoclax in CLL, AML and multiple myeloma. J Pers Med 2021;11:463. 13. Mei M, Aldoss I, Marcucci G, Pullarkat V. Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: update on clinical trial data and practical considerations for use. Am J Hematol 2019;94:358-62. 14. Rausch CR, DiNardo CD, Maiti A, et al. Venetoclax dosing in combination with antifungal agents: real world experience in patients with acute myeloid leukemia. Blood (ASH Annual Meeting Abstracts) 2019;134(Suppl 1):2640.","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/50/e0/br-58-2-120.PMC10310490.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5045/br.2023.2023084","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

REFERENCES 1. Munker R, Labopin M, Esteve J, Schmid C, Mohty M, Nagler A. Mixed phenotype acute leukemia: outcomes with allogeneic stem cell transplantation. A retrospective study from the Acute Leukemia Working Party of the EBMT. Haematologica 2017; 102:2134-40. 2. Shimoni A. Relapse of acute leukemia after a second allogeneic stemcell transplantation; is there any hope for cure? Bone Marrow Transplant 2022;57:336-7. 3. DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 2020;383:617‐29. 4. Schuler E, Wagner-Drouet EM, Ajib S, et al. Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group. Ann Hematol 2021;100:959‐68. 5. Qasrawi A, Gomes V, Chacko CA, et al. Acute undifferentiated leukemia: data on incidence and outcomes from a large population-based database. Leuk Res 2020;89:106301. 6. Pan R, Hogdal LJ, Benito JM, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov 2014;4:362‐75. 7. Fleischmann M, Scholl S, Frietsch JJ, et al. Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia. J Cancer Res Clin Oncol 2022;148:3191‐202. 8. Pratz KW, Jonas BA, Pullarkat V, et al. Measurable residual disease response and prognosis in treatment-naïve acute myeloid leukemia with venetoclax and azacitidine. J Clin Oncol 2022; 40:855‐65. 9. Wang N, He J, Liu F. Venetoclax in combination with hypomethylating agents for the treatment of treatment-naive B/myeloid mixed-phenotype acute leukemia and relapsed/refractory acute myeloid leukemia: a report of 3 cases. Chemotherapy 2022;67:178-82. 10. Klocke H, Dong ZM, O'Brien C, et al. Venetoclax and decitabine for T/myeloid mixed-phenotype acute leukemia not otherwise specified (MPAL NOS). Case Rep Hematol 2020;2020:8811673. 11. Zhao P, Ni M, Ma D, et al. Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation. Ann Hematol 2022;101:119‐30. 12. Lasica M, Anderson MA. Review of venetoclax in CLL, AML and multiple myeloma. J Pers Med 2021;11:463. 13. Mei M, Aldoss I, Marcucci G, Pullarkat V. Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: update on clinical trial data and practical considerations for use. Am J Hematol 2019;94:358-62. 14. Rausch CR, DiNardo CD, Maiti A, et al. Venetoclax dosing in combination with antifungal agents: real world experience in patients with acute myeloid leukemia. Blood (ASH Annual Meeting Abstracts) 2019;134(Suppl 1):2640.

Abstract Image